Sprague-Dawley (SD) Rat Adipose-Derived Mesenchymal Stem Cells

  • Specification
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C1310
Description
SD Rat Adipose-derived mesenchymal stem cells were taken from the inguinal fat of SD rats. These cells can express specific proteins of ADSCs and have strong proliferation and multidirectional differentiation capabilities. It can be used as a cell model to study proliferation, aging, immunity, differentiation and transplantation.
Species
Rat
Recommended Medium
SD Rat Adipose-derived Mesenchymal Stem Cells Complete Medium
Application
For Research Use Only
Shipping
Dry Ice
Quality Control
Sterility, Safety, HIV/viruses, bacteria, fungi: negative.
Storage and Shipping
Remove cryovials (dry ice packaging) and place the vial into liquid nitrogen for storage. Alternatively, thaw and use the cells immediately.
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

Enhanced Mesenchymal Stromal Cells or Erythropoietin Provide Long-Term Functional Benefit After Neonatal Stroke

Stroke | DOI | Paper |

Background

Perinatal stroke causes lifelong neurobehavioral deficits, and effective delayed therapies are needed. This study tested intranasal mesenchymal stromal cells (MSCs), MSCs preexposed to erythropoietin (MSC/EPO), and multidose systemic EPO in a postnatal day 10 rat transient middle cerebral artery occlusion model. Treatments were given 3 or 7 days after injury, with behavioral and histological assessment at 2 months. MSC, MSC/EPO, and EPO improved brain volume; MSC/EPO and EPO improved recognition memory. Multidose EPO provided the broadest long-term benefit, including reduced anxiety and improved exploration.

Key Findings

Delayed single-dose intranasal MSC/EPO and multidose systemic EPO both produced long-term functional and histological benefit after neonatal stroke. At 2 months, MSC, MSC/EPO, and EPO3 all improved hemispheric brain volume when administered 3 or 7 days after middle cerebral artery occlusion, though injured volumes remained below sham. MSC/EPO enhanced recognition memory at both day 3 and day 7. Standard MSC showed limited sensorimotor benefit (improved cylinder rearing at day 7) and no consistent cognitive improvement. Multidose EPO (EPO3) had the most consistent long-term benefit: it improved recognition memory at both time points and, with day 7 treatment, increased open-field center entries, center duration, rearing, and locomotion while reducing anxiety. Cell-free conditioned media from MSC/EPO improved brain volume at day 3 but not behavior. No sex-based differences were observed. The authors conclude that EPO may represent a final common pathway for long-term repair, though mechanisms remain unclear.

Contribution

Creative Bioarray provided the rat Sprague-Dawley adipose-derived MSCs used for intranasal MSC and MSC/EPO therapies. These cells were characterized for differentiation potential and surface markers (CD29/CD44/CD90/CD105 positive; CD11b/CD34/CD45 negative), supporting the study’s comparison of standard and EPO-preexposed MSC treatment after neonatal stroke.

Fig. 1.

Ask a Question

Write your own review

For research use only. Not for any other purpose.

Hot Products